comparemela.com

Latest Breaking News On - Nantahala capital partners - Page 1 : comparemela.com

Labaton Sucharow LLP Announce Notice of Pendency and Proposed Settlement For All Record Holders and Beneficial Owners of QAD Inc. Class A Common Stock

Labaton Sucharow LLP Announce Notice of Pendency and Proposed Settlement For All Record Holders and Beneficial Owners of QAD Inc. Class A Common Stock
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

State-of-delaware
Delaware
United-states
New-castle-county
Ned-weinberger
Pamelam-lopker
Anton-chilton
Scottj-adelson
Kathleenm-crusco
Paulj-fioravanti-jr
Thoma-bravo
Office-of-the-register-in-chancery

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

California
United-states
San-francisco
Shalabh-gupta
Gaurav-aggarwal
Bmw
Rosalind-advisors-inc
Drug-administration
Logos-capital
Nantahala-capital-partners
Rosalind-advisors
Vivo-capital

Unicycive Therapeutics, Inc (UNCY) Enters Up to $130M Financing to Commercialize and Launch Investigational New Drug Renazorb

Unicycive Therapeutics, Inc (UNCY) Enters Up to $130M Financing to Commercialize and Launch Investigational New Drug Renazorb
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Shalabh-gupta
Anne-marie-fieldsstern
Gaurav-aggarwal
Drug-administration
Nasdaq
Company-or-unicycive
Exchange-commission
Maxim-group
Rosalind-advisors-inc
Unicycive-therapeutics-inc
Company-seriesa-convertible-preferred-stock

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

06.03.2023 - $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital . Seite 1

Shalabh-gupta
Gaurav-aggarwal
Company-or-unicycive
Rosalind-advisors-inc
Unicycive-therapeutics-inc
Drug-administration
Nasdaq
Vivo-capital
Logos-capital
Nantahala-capital-partners
Rosalind-advisors
Managing-director

vimarsana © 2020. All Rights Reserved.